Allergan (AGN) Stock May Trade Higher; Jim Cramer Calls Kythera Acquisition 'Brilliant'

NEW YORK (TheStreet) -- Shares of Allergan Plc (AGN) may trade higher after the company announced it is buying Kythera Biopharmaceuticals (KYTH) in a cash-and-stock deal for about $2.1 billion, or $75 per share.

TheStreet's Jim Cramer, Portfolio Manager of the Action Alerts PLUS Charitable Trust Portfolio says, "This is BRILLIANT! Allergan CEO Brent Saunders now owns 'the face' - the most important asset in the world!"

With the acquisition,Allergan plans to expand its line of cosmetic treatments.

Allergan will gain access to Kybella, Kythera's first and only approved non-surgical treatment to reduce fat under the chin.

The equity value of the deal is about $1.94 billion, according to Thomson Reuters.

Kythera shareholders will get 80% of the purchase price in cash, and 20% in new Allergan shares. The deal must be approved by Kythera shareholders.

Allergan stock closed at $298.02 yesterday.

Allergan is a global pharmaceutical company that made wrinkle treatment Botox. The company is focused on developing, manufacturing and commercializing branded pharmaceuticals, generic and over-the-counter medicines, and biologic products.

Insight from TheStreet's Research Team:

Jim Cramer, Portfolio Manager of Action Alerts PLUS and Jack Mohr, Director of Research mentioned Allergan in a recent post. Here is a snippet of what Jim Cramer and Jack Mohr had to say about the stock:

We believe this is a genius deal for Allergan, which this week officially changed its name from Actavis. KYTH is known for having the first and only approved non-surgical treatment for contouring moderate to severe submental fullness, a.k.a. double chin, with its drug Kybella. This perfectly complements the Allergan name, which is known for the famous anti-wrinkle injection Botox, as the company now owns the most important piece of human real estate -- the face -- through its various treatments directed toward the forehead, eyes, mouth and now the chin.

- Jim Cramer and Jack Mohr, ' Kythera Deal a Genius Move by Allergan ' originally published 6/17/2015 on ActionAlertsPLUS.com.

Want more information like this from Jim Cramer and Jack Mohr BEFORE your stock moves? Learn more about ActionAlertsPLUS.com now.

Separately, TheStreet Ratings team rates Allergan PLC as a Hold with a ratings score of C.
 
You can view the full analysis from the report here:  AGN Rating Report

More from Markets

REPLAY: Jim Cramer on How to Navigate the Stock Market Amid Tariff Worries

REPLAY: Jim Cramer on How to Navigate the Stock Market Amid Tariff Worries

Global Markets Hit Hard; AMC Entertainment Sells Stake in Ad Unit -- ICYMI

Global Markets Hit Hard; AMC Entertainment Sells Stake in Ad Unit -- ICYMI

CVS, Walgreens and Citigroup: Cramer's 'Off the Charts'

CVS, Walgreens and Citigroup: Cramer's 'Off the Charts'

Jim Cramer: 4 Stocks Could Get Throttled By a 'Knock Down Drag Out' With China

Jim Cramer: 4 Stocks Could Get Throttled By a 'Knock Down Drag Out' With China

General Electric Booted From Dow, Replaced by Walgreens

General Electric Booted From Dow, Replaced by Walgreens